Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri (Pamasha Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- Pamasha Pharmaceuticals
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Abdoease is an orally administered probiotic dietary supplement developed and marketed by Pamasha Pharmaceuticals. Formulated as a capsule containing at least 10 billion viable cells of *Lactobacillus reuteri* (specifically the DSMZ 17648 strain), Abdoease is designed to support digestive health, maintain gastrointestinal microbial harmony, and promote overall gut health. The active ingredient, *Lactobacillus reuteri*, works by colonizing the gastrointestinal tract, restoring the natural balance of the intestinal microbiota, and strengthening the gut mucosal barrier against pathogens. Additionally, the DSMZ 17648 strain is known to specifically co-aggregate with *Helicobacter pylori* in the stomach, facilitating its clearance and supporting gastric health.
- Brand names
- Abdoease
- Other names
- Lactobacillus reuteriLactobacillus reuteri DSMZ 17648Limosilactobacillus reuteriLimosilactobacillus reuteri DSMZ 17648
Beyond the preview
Go deeper on lactobacillus reuteri (Pamasha Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri (Pamasha Pharmaceuticals).